Green Thumb Industries (GTBIF) Cash from Investing Activities (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Cash from Investing Activities came in at -$20.6 million in Q1 2026, up 32.69% YoY from -$15.5 million in Q1 2025, and down 7.44% on a QoQ basis from -$19.2 million in Q4 2025.
Green Thumb Industries (GTBIF) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Cash from Investing Activities data on file, last reported at -$20.6 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 32.69% year-over-year to -$20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$120.4 million (down 9.61% YoY) and the FY2025 annual result came in at -$130.4 million, down 45.63% from the prior year.
- Cash from Investing Activities declined to -$20.6 million in Q1 2026, from -$19.2 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$10.3 million in Q1 2024 to a low of -$100.4 million in Q1 2022.
- A 5-year average of -$40.5 million and a median of -$36.1 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 1286.56% — and 2024, when it surged 84.65%.
- Tracing GTBIF's Cash from Investing Activities over 5 years: stood at -$58.8 million in 2022, then soared by 31.16% to -$40.5 million in 2023, then gained by 10.78% to -$36.1 million in 2024, then soared by 46.95% to -$19.2 million in 2025, then declined by 7.44% to -$20.6 million in 2026.
- The last three Cash from Investing Activities figures came in at -$20.6 million (Q1 2026), -$19.2 million (Q4 2025), and -$13.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Green Thumb Industries | 1.65 Bn | 1.37 Bn | 137.87 Mn | -33.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.98 Mn |
| Jun 30, 2026 | -33.98 Mn |
| Mar 31, 2026 | -20.58 Mn |
| Mar 31, 2026 | -20.58 Mn |
| Dec 31, 2025 | -19.15 Mn |
| Dec 31, 2025 | -19.15 Mn |
| Sep 30, 2025 | -13.00 Mn |
| Sep 30, 2025 | -13.00 Mn |
| Jun 30, 2025 | -67.67 Mn |
| Jun 30, 2025 | -67.67 Mn |
| Mar 31, 2025 | -30.57 Mn |
| Mar 31, 2025 | -30.57 Mn |
| Dec 31, 2024 | -36.10 Mn |
| Dec 31, 2024 | -36.10 Mn |
| Sep 30, 2024 | -19.11 Mn |
| Sep 30, 2024 | -19.11 Mn |
| Jun 30, 2024 | -24.06 Mn |
| Jun 30, 2024 | -24.06 Mn |
| Mar 31, 2024 | -10.27 Mn |
| Mar 31, 2024 | -10.27 Mn |